LXRX — Lexicon Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $662.98m
- $523.81m
- $49.80m
Lexicon sinks as FDA advisers vote against add-on drug for type 1 diabetes
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes (updated)
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
Brief: Lexicon Announces Completion Of Screening In Phase 2B Progress Study Of Lx9211
Brief: Lexicon Pharmaceuticals - May Get From Viatris Up To $185 Million Upon Achievement Of Specified Sales Milestones Under License Deal
Brief: Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals For Sotagliflozin In All Markets Outside Of The U.S. And Europe
Brief: New Secondary Analysis Of Phase 3 Data Demonstrates That Inpefa (Sotagliflozin) Benefited Heart Failure Patients Regardless Of Diabetes Duration
Brief: Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
U.S. STOCKS ON THE MOVE-Paysafe, HUYA, Oklo
U.S. STOCKS ON THE MOVE-Penumbra, Talen Energy, Paysafe
Lexicon Pharma rises on strategic review announcement
Brief: Lexicon Pharmaceuticals Announces Strategic Repositioning
Lexicon Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alexander & Baldwin, Instructure Holdings, RPM International
Brief: Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
Brief: Lexicon Pharmaceuticals On June 28, Co, Unit Entered Sixth Amendment To Loan & Security Agreement With Oxford Finance LLC
U.S. STOCKS ON THE MOVE-FactSet, Ryan Specialty, Sarepta
Lexicon gains on resubmission of marketing application for diabetes drug
Brief: Lexicon Pharmaceuticals Resubmits Marketing Application For Diabetes Drug